Nat Biotech:华人科学家分析13个著名实验室海拉细胞发现,它们或已进化成新“物种”,癌症研究现危机

2019-02-24 奇点糕 奇点网

2016年,《自然》杂志做的一项调查显示,超过70%的研究者称无法再现其他科学家的实验。这让科学界出现了“再现危机”,也严重阻碍了科学的进步和科研成果的转化。 去年8月,我们曾报道,科学家在数据库中发现,科研机构的癌细胞系竟然在偷偷进化,甚至对药物的反应也产生了大幅度的变化,严重影响了抗癌药物的研发。这绝对值得科研人员警惕。 最近,耶鲁大学的刘延盛实验室和苏黎世联邦理工大学的Ruedi A

2016年,《自然》杂志做的一项调查显示,超过70%的研究者称无法再现其他科学家的实验。这让科学界出现了“再现危机”,也严重阻碍了科学的进步和科研成果的转化。

去年8月,我们曾报道,科学家在数据库中发现,科研机构的癌细胞系竟然在偷偷进化,甚至对药物的反应也产生了大幅度的变化,严重影响了抗癌药物的研发。这绝对值得科研人员警惕。

最近,耶鲁大学的刘延盛实验室和苏黎世联邦理工大学的Ruedi Aebersold实验室合作,对6个国家13个顶级实验室的海拉细胞系(一种使用最广泛的癌症细胞系),进行细致的分析,发现不同实验室的海拉细胞系从基因组到转录组,再到蛋白组和细胞表型,都发生了翻天覆地的变化。

比如,对于同一种海拉细胞系,在同样培养条件下,细胞数量翻倍所需要的时间竟然存在成倍的差距。其他生理功能,如对细菌感染的反应也截然不同。甚至细胞只要多传一两代,整个“胞”就都变了样。相关研究发表在顶级学术期刊Nature Biotechnology上。

左:刘延盛  右:Ruedi Aebersold

这项研究将实验无法再现的担忧推到了另一个层次,也提醒还在实验室辛辛苦苦用细胞系筛药、研究机制的同学们注意了,用差异如此巨大的材料去做实验,怎么可能做出一致结果!(文章后面有作者提出的应对措施)

《自然》提出“再现危机”时,确实让学术界慌了神,如此大面积的实验无法再现,那直接动摇科学界的根基了。

如果是说出现了大规模的造假,那显然是太过阴谋论了,毕竟学术界一向是对学术不端零容忍的。况且这些年来,科技的进步对世界的改变有目共睹。

那究竟是什么原因造成了这个结果呢?

生物学研究,尤其是癌症研究,大部分都是从细胞系从出发的。而细胞材料本身的变化肯定是一个核心影响因素。

比如之前就有报道称,有科研机构的细胞系标签打错,影响了无数实验室的研究。

打错标签,在哪里都存在......

当然,还有更重要的一个问题,那就是细胞系自身基因组变异的问题了。毕竟不同地方细胞的培养条件都不同,而细胞经过反复传代,遗传物质也会有变化。例如,我们开头所提到的癌细胞系的进化。

而说到细胞系,海拉细胞系大家一定最熟悉了。从上世纪50年代以来,海拉细胞系在世界各个实验室中“流传”。目前,已有超过100000篇论文的研究使用或直接引用了来自海拉细胞系的实验结果。可见海拉细胞影响之大。

那这些使用广泛的海拉细胞系之间到底有多大差别呢?我们并不清楚。这个问题迫切需要阐明。

对此,刘延盛博士带领的联合团队进行详细的研究。他们从各大实验室搜集了海拉细胞系,利用基因芯片技术(微阵列比较基因组杂交技术)、转录组测序以及蛋白质谱技术等,对这些细胞系进行分析,并且还测量了细胞的各种生理表型,系统地比较了各细胞系的差异。

首先是基因组的变化。研究人员发现不同实验室的海拉细胞系之间,在基因组结构上就有很大的差异。很多细胞中,基因的拷贝数都不一样,甚至染色体倍数都发生了改变。染色体数量改变,那随随便便就影响上千个基因了。

不同来源的海拉细胞系基因拷贝数差别明显

基因表达谱的变化更明显。科学家让所有的细胞系都处于静息状态,不给刺激,然后进行转录组和蛋白组测序,比较了海拉细胞系的两种类型:CCL2和Kyoto的表达谱,定量分析了11365个转录本、5030种蛋白的水平。通过主成分分析表明,两种细胞系的表达谱在各个层面都有显着差异。

从mRNA到蛋白质,差异明显

不仅如此,比较同一个来源但不同代数的海拉细胞系,发现12代的细胞与14代的细胞之间竟然有731个基因的表达存在显着差异,并且有166个反应到了蛋白水平上。而第七代与第50代之间的差异就更大了,整合素信号通路、内切酶活性的调控通路、炎症反应通路这些非常基础的功能,都有大幅的改变。用不同代的细胞系做实验的同学可得注意了。

基因组——转录组——蛋白组都有大量变化,那细胞本身的生理表型也就不可避免的会改变了。

研究人员对不同来源的细胞系进行培养,发现细胞数量翻倍所需的时间,竟然从17.5个小时到32.3个小时不等。而这些细胞中,63种细胞周期相关蛋白的表达也差异明显。

不同来源的海拉细胞,复制速率差异巨大

随后,研究人员用沙门氏菌感染不同的来源、不同代数的海拉细胞系,发现感染率有很大的不同。而在应对细菌感染时,不同细胞系表达的蛋白差别很大,如下图。

左图:不同细胞的感染复数   右图:不同细胞感染后蛋白表达的差异

事实上,这一项研究无法穷尽不同来源细胞系之间的差异,但结果仍然让人触目惊心。

本研究是重点关注了海拉细胞系,但这不意味着其他细胞系就没有问题,比如我们另一篇文章中提到了MCF-7乳腺癌细胞系。因此,细胞系的变异问题可能是一个普遍的现象,如果不加以重视,可能会严重阻碍生命科学和医学的发展。

对此,本论文的作者也发出了如下几个倡议:

第一,未来海拉细胞系相关的研究,都至少注明是CCL2细胞系还是 Kyoto细胞系;

第二,使用早期传代的细胞系进行实验,并标明所用细胞系的代数;

第三,对于癌细胞重要生理表型的观察,应使用不同样本,不同细胞模型,不同实验室来源的细胞系进行对比。

第四,呼吁科学家团体展开讨论,并考虑运用更加精确的分子特征,对细胞进行认证。

原始出处:Yansheng Liu, Yang Mi, Torsten Mueller, et al. Multi-omic measurements of heterogeneity in HeLa cells across laboratories. Nat Biotech. 18 February 2019

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1927705, encodeId=eff0192e705e5, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Dec 11 22:35:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918552, encodeId=f88b1918552c7, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Nov 19 07:35:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652326, encodeId=18791652326a8, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Mar 09 20:35:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883611, encodeId=bc5c188361190, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Aug 01 00:35:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514190, encodeId=61cc151419055, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Mon Feb 25 15:35:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582033, encodeId=2a7d15820339b, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Mon Feb 25 15:35:00 CST 2019, time=2019-02-25, status=1, ipAttribution=)]
    2019-12-11 cathymary
  2. [GetPortalCommentsPageByObjectIdResponse(id=1927705, encodeId=eff0192e705e5, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Dec 11 22:35:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918552, encodeId=f88b1918552c7, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Nov 19 07:35:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652326, encodeId=18791652326a8, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Mar 09 20:35:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883611, encodeId=bc5c188361190, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Aug 01 00:35:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514190, encodeId=61cc151419055, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Mon Feb 25 15:35:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582033, encodeId=2a7d15820339b, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Mon Feb 25 15:35:00 CST 2019, time=2019-02-25, status=1, ipAttribution=)]
    2019-11-19 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1927705, encodeId=eff0192e705e5, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Dec 11 22:35:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918552, encodeId=f88b1918552c7, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Nov 19 07:35:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652326, encodeId=18791652326a8, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Mar 09 20:35:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883611, encodeId=bc5c188361190, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Aug 01 00:35:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514190, encodeId=61cc151419055, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Mon Feb 25 15:35:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582033, encodeId=2a7d15820339b, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Mon Feb 25 15:35:00 CST 2019, time=2019-02-25, status=1, ipAttribution=)]
    2019-03-09 shock_melon
  4. [GetPortalCommentsPageByObjectIdResponse(id=1927705, encodeId=eff0192e705e5, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Dec 11 22:35:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918552, encodeId=f88b1918552c7, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Nov 19 07:35:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652326, encodeId=18791652326a8, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Mar 09 20:35:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883611, encodeId=bc5c188361190, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Aug 01 00:35:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514190, encodeId=61cc151419055, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Mon Feb 25 15:35:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582033, encodeId=2a7d15820339b, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Mon Feb 25 15:35:00 CST 2019, time=2019-02-25, status=1, ipAttribution=)]
    2019-08-01 liye789132251
  5. [GetPortalCommentsPageByObjectIdResponse(id=1927705, encodeId=eff0192e705e5, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Dec 11 22:35:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918552, encodeId=f88b1918552c7, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Nov 19 07:35:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652326, encodeId=18791652326a8, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Mar 09 20:35:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883611, encodeId=bc5c188361190, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Aug 01 00:35:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514190, encodeId=61cc151419055, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Mon Feb 25 15:35:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582033, encodeId=2a7d15820339b, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Mon Feb 25 15:35:00 CST 2019, time=2019-02-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1927705, encodeId=eff0192e705e5, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Dec 11 22:35:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918552, encodeId=f88b1918552c7, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Nov 19 07:35:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652326, encodeId=18791652326a8, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sat Mar 09 20:35:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883611, encodeId=bc5c188361190, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Aug 01 00:35:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514190, encodeId=61cc151419055, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Mon Feb 25 15:35:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582033, encodeId=2a7d15820339b, content=<a href='/topic/show?id=830c35868ec' target=_blank style='color:#2F92EE;'>#华人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35868, encryptionId=830c35868ec, topicName=华人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f7716881423, createdName=ms4468361851264128, createdTime=Mon Feb 25 15:35:00 CST 2019, time=2019-02-25, status=1, ipAttribution=)]

相关资讯

改变人类医学史的海拉细胞

它的名字叫海拉细胞,是医学史上首例经体外培养而 “永生不死” 的细胞;它帮助医学家解开了癌症、病毒如何影响人体的奥秘,促成了体外受精、克隆技术、基因图谱等无数医学突破,涉及几乎所有医学研究领域;它曾被用于调查原子弹爆炸对人体造成的影响,也曾搭载美国和苏联的火箭升空,被人们用于研究失重状态下的细胞增殖;进入 21 世纪以来,已经有 5 个基于海拉细胞的研究成果获得了诺贝尔奖……